CL2012002744A1 - Compuesto inhibidor no nucleosídico de la transcriptasa inversa derivado de 3-(hidrocarbiloxi aromático y alifático opcionalmente sustituido)-1-[(5-oxo-4,5-dihidro-1h-1,2,4-triazol-3-il)metil])-piridin-2(ih)-ona; composición farmacéutica que lo comprende útil en la profilaxis y tratamiento de la infección por vih y sida. - Google Patents

Compuesto inhibidor no nucleosídico de la transcriptasa inversa derivado de 3-(hidrocarbiloxi aromático y alifático opcionalmente sustituido)-1-[(5-oxo-4,5-dihidro-1h-1,2,4-triazol-3-il)metil])-piridin-2(ih)-ona; composición farmacéutica que lo comprende útil en la profilaxis y tratamiento de la infección por vih y sida.

Info

Publication number
CL2012002744A1
CL2012002744A1 CL2012002744A CL2012002744A CL2012002744A1 CL 2012002744 A1 CL2012002744 A1 CL 2012002744A1 CL 2012002744 A CL2012002744 A CL 2012002744A CL 2012002744 A CL2012002744 A CL 2012002744A CL 2012002744 A1 CL2012002744 A1 CL 2012002744A1
Authority
CL
Chile
Prior art keywords
triazol
pyridin
prophylaxis
dihydro
oxo
Prior art date
Application number
CL2012002744A
Other languages
English (en)
Spanish (es)
Inventor
Jason Burch
Bernard Cote
Natalie Nguyen
Chunsing Li
Onge Miguel St
Danny Gauvreau
Original Assignee
Merck Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44710363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012002744(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Canada Inc filed Critical Merck Canada Inc
Publication of CL2012002744A1 publication Critical patent/CL2012002744A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2012002744A 2010-03-30 2012-09-28 Compuesto inhibidor no nucleosídico de la transcriptasa inversa derivado de 3-(hidrocarbiloxi aromático y alifático opcionalmente sustituido)-1-[(5-oxo-4,5-dihidro-1h-1,2,4-triazol-3-il)metil])-piridin-2(ih)-ona; composición farmacéutica que lo comprende útil en la profilaxis y tratamiento de la infección por vih y sida. CL2012002744A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31882410P 2010-03-30 2010-03-30
US32157310P 2010-04-07 2010-04-07

Publications (1)

Publication Number Publication Date
CL2012002744A1 true CL2012002744A1 (es) 2012-12-14

Family

ID=44710363

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012002744A CL2012002744A1 (es) 2010-03-30 2012-09-28 Compuesto inhibidor no nucleosídico de la transcriptasa inversa derivado de 3-(hidrocarbiloxi aromático y alifático opcionalmente sustituido)-1-[(5-oxo-4,5-dihidro-1h-1,2,4-triazol-3-il)metil])-piridin-2(ih)-ona; composición farmacéutica que lo comprende útil en la profilaxis y tratamiento de la infección por vih y sida.

Country Status (44)

Country Link
US (2) US8486975B2 (enExample)
EP (2) EP2924034B1 (enExample)
JP (2) JP5281718B2 (enExample)
KR (1) KR101421861B1 (enExample)
CN (1) CN102971308B (enExample)
AR (1) AR080859A1 (enExample)
AU (1) AU2011235568B2 (enExample)
BR (1) BR112012024691B1 (enExample)
CA (1) CA2794377C (enExample)
CL (1) CL2012002744A1 (enExample)
CO (1) CO6630126A2 (enExample)
CR (1) CR20120503A (enExample)
CY (3) CY1118774T1 (enExample)
DK (2) DK2924034T3 (enExample)
DO (1) DOP2012000256A (enExample)
EA (1) EA024804B1 (enExample)
EC (1) ECSP12012201A (enExample)
ES (2) ES2609636T3 (enExample)
FI (1) FIC20190021I1 (enExample)
GE (1) GEP20156368B (enExample)
HN (1) HN2012002039A (enExample)
HR (2) HRP20150427T1 (enExample)
HU (4) HUE025336T2 (enExample)
IL (2) IL222030A (enExample)
LT (3) LT2924034T (enExample)
LU (2) LUC00114I2 (enExample)
MA (1) MA34170B1 (enExample)
ME (2) ME02570B (enExample)
MX (1) MX2012011379A (enExample)
MY (1) MY163979A (enExample)
NI (1) NI201200146A (enExample)
NL (1) NL300980I2 (enExample)
NO (2) NO2019019I1 (enExample)
NZ (1) NZ602670A (enExample)
PE (1) PE20130158A1 (enExample)
PH (1) PH12012501923A1 (enExample)
PL (2) PL2924034T3 (enExample)
PT (2) PT2924034T (enExample)
RS (2) RS55505B1 (enExample)
SG (1) SG184347A1 (enExample)
SI (2) SI2924034T1 (enExample)
TN (1) TN2012000455A1 (enExample)
TW (1) TWI458719B (enExample)
WO (1) WO2011120133A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012011379A (es) * 2010-03-30 2012-11-30 Merck Canada Inc Inhibidores no nucleosidicos de la transcriptasa inversa.
WO2012048113A2 (en) 2010-10-07 2012-04-12 The General Hospital Corporation Biomarkers of cancer
EP2900240B1 (en) * 2012-09-26 2020-01-08 Merck Sharp & Dohme Corp. Crystalline form of a reverse transcriptase inhibitor
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
CN104994855B (zh) * 2012-12-05 2018-06-05 默沙东公司 制备逆转录酶抑制剂的方法
EP3071037A4 (en) * 2013-11-22 2017-08-02 Merck Sharp & Dohme Corp. Composition of a non-nucleoside reverse transcriptase inhibitor
KR101803671B1 (ko) * 2013-12-04 2017-11-30 머크 샤프 앤드 돔 코포레이션 역전사효소 억제제의 제조 방법
SI3125894T1 (sl) 2014-04-01 2020-12-31 Merck Sharp & Dohme Corp. Predzdravila inhibitorjev reverzne transkriptaze HIV
EP3161159B1 (en) 2014-06-25 2020-08-05 The General Hospital Corporation Targeting human satellite ii (hsatii)
RU2736941C2 (ru) 2015-12-02 2020-11-23 Мерк Шарп энд Доум Корп. Фармацевтические композиции, содержащие доравирин, тенофовира дизопроксила фумарат и ламивудин
WO2018175271A1 (en) * 2017-03-24 2018-09-27 Merck Sharp & Dohme Corp. Formulation for parenteral administration
RU2019136678A (ru) 2017-04-18 2021-05-18 Сипла Лимитед Комбинированная терапия для применения в лечении ретровирусных инфекций
EP4317972A3 (en) 2018-02-06 2024-03-13 The General Hospital Corporation Repeat rna as biomarkers of tumor immune response
WO2020018352A1 (en) 2018-07-17 2020-01-23 Merck Sharp & Dohme Corp. Hiv drug combination for increasing barrier against resistance
MX2021007382A (es) 2018-12-18 2021-07-15 Merck Sharp & Dohme Llc Derivados de pirimidona como agentes citotoxicos selectivos contra celulas infectadas por vih.
CN110801455B (zh) * 2019-11-12 2020-06-02 河北医科大学第二医院 用于治疗mrsa的药物组合物及其应用
CN114163309B (zh) * 2021-12-27 2023-04-25 甘肃皓天医药科技有限责任公司 一种多拉韦林中间体的制备方法
CN114349690B (zh) * 2022-02-15 2023-04-25 甘肃皓天医药科技有限责任公司 一种多拉韦林中间体合成方法
CN116903590A (zh) * 2023-06-06 2023-10-20 延边大学 一种含杂环结构的吡啶酮类化合物及其制备方法和用途
CN120157613A (zh) * 2023-12-15 2025-06-17 山东诚创蓝海医药科技有限公司 多拉韦林中间体及其应用和合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904045D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
TW200423930A (en) * 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
TW200505441A (en) * 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
WO2004085406A1 (en) 2003-03-24 2004-10-07 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
AU2005235692B2 (en) 2004-04-23 2011-11-10 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
JP2008525419A (ja) 2004-12-22 2008-07-17 ファイザー・リミテッド Hiv−1逆転写酵素の非ヌクレオシド阻害剤
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
ES2320042T3 (es) 2005-10-19 2009-05-18 F. Hoffmann-La Roche Ag Inhibidores de transcriptasa reversa con nucleosidos de n-fenil fenilacetamida.
EP1940781A1 (en) 2005-10-19 2008-07-09 F.Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
TW200831085A (en) 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
CN101952274A (zh) 2007-11-20 2011-01-19 默沙东公司 非核苷逆转录酶抑制剂
MX2012011379A (es) * 2010-03-30 2012-11-30 Merck Canada Inc Inhibidores no nucleosidicos de la transcriptasa inversa.

Also Published As

Publication number Publication date
EA024804B1 (ru) 2016-10-31
LUC00113I9 (enExample) 2024-06-07
EP2552902A1 (en) 2013-02-06
AR080859A1 (es) 2012-05-16
CY2019026I1 (el) 2020-05-29
CR20120503A (es) 2013-01-09
KR20120128703A (ko) 2012-11-27
NL300980I2 (nl) 2021-06-17
CY2019025I2 (el) 2019-11-27
IL222030A (en) 2014-07-31
US20110245296A1 (en) 2011-10-06
HUS1900022I1 (hu) 2019-05-28
KR101421861B1 (ko) 2014-07-22
CY2019025I1 (el) 2019-11-27
EA201290976A1 (ru) 2013-03-29
IL233334A (en) 2015-09-24
CO6630126A2 (es) 2013-03-01
EP2552902B1 (en) 2015-03-11
TN2012000455A1 (en) 2014-01-30
EP2924034A1 (en) 2015-09-30
NO2019018I1 (no) 2019-04-24
BR112012024691B1 (pt) 2020-11-17
GEP20156368B (en) 2015-09-25
PL2552902T3 (pl) 2015-10-30
PT2924034T (pt) 2017-01-06
LT2924034T (lt) 2016-12-27
PT2552902E (pt) 2015-06-02
HK1175471A1 (en) 2013-07-05
JP2013209405A (ja) 2013-10-10
DK2924034T3 (en) 2017-02-06
ECSP12012201A (es) 2012-10-30
HRP20161680T1 (hr) 2017-01-27
HN2012002039A (es) 2015-08-24
SI2924034T1 (sl) 2017-05-31
LTC2552902I2 (lt) 2019-12-10
SI2552902T1 (sl) 2015-10-30
CN102971308B (zh) 2015-02-04
MX2012011379A (es) 2012-11-30
AU2011235568A1 (en) 2012-11-01
SG184347A1 (en) 2012-11-29
NO2019019I1 (no) 2019-04-24
JP2013510800A (ja) 2013-03-28
HUE025336T2 (en) 2016-03-29
AU2011235568B2 (en) 2013-09-12
ES2536295T3 (es) 2015-05-22
MY163979A (en) 2017-11-15
CN102971308A (zh) 2013-03-13
LTC2924034I2 (lt) 2020-10-12
TWI458719B (zh) 2014-11-01
TW201139409A (en) 2011-11-16
PH12012501923A1 (en) 2013-02-04
BR112012024691A2 (pt) 2019-07-02
CA2794377A1 (en) 2011-10-06
HUS1900021I1 (hu) 2019-05-28
LTPA2019506I1 (lt) 2019-04-25
EP2924034B1 (en) 2016-11-02
HUE031785T2 (en) 2017-08-28
HK1209121A1 (en) 2016-03-24
CA2794377C (en) 2015-06-16
PL2924034T3 (pl) 2017-07-31
LTPA2019507I1 (lt) 2019-04-25
US8486975B2 (en) 2013-07-16
JP5886790B2 (ja) 2016-03-16
NL300980I1 (nl) 2019-04-24
ME02181B (me) 2015-10-20
HRP20150427T1 (hr) 2015-07-03
RS55505B1 (sr) 2017-05-31
ES2609636T3 (es) 2017-04-21
CY1118774T1 (el) 2017-07-12
LUC00114I1 (enExample) 2019-04-17
EP2552902A4 (en) 2013-09-04
ME02570B (me) 2017-06-20
DOP2012000256A (es) 2012-12-15
NZ602670A (en) 2014-09-26
FIC20190021I1 (fi) 2019-04-17
LUC00113I2 (enExample) 2024-05-22
LUC00114I2 (enExample) 2020-07-10
CY2019026I2 (el) 2020-05-29
PE20130158A1 (es) 2013-02-28
JP5281718B2 (ja) 2013-09-04
WO2011120133A1 (en) 2011-10-06
IL233334A0 (en) 2014-09-01
DK2552902T3 (en) 2015-06-15
MA34170B1 (fr) 2013-04-03
NI201200146A (es) 2013-03-18
RS54017B1 (sr) 2015-10-30
US20130296382A1 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
ZA202301437B (en) Compounds and methods for treatment of viral infections
HN2012002039A (es) Inhibidores no nucleosidicos de la transcriptasa inversa
MX2009005881A (es) Derivados de 2-(piperidin-4-il)-4-fenoxi o fenilamino-pirimidina como inhibidores de la transcriptasa inversa no nucleosida.
SV2009003294A (es) Inhibidores de transcriptasa inversa no nucleosidicos
CL2008003406A1 (es) Compuestos derivados de quinolina; composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vih.
ECSP066826A (es) Inhibidores de integrasa de vih
GT201500088A (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
NZ733135A (en) Fused pyrimidine compounds for the treatment of hiv
CR9694A (es) Inhibidores de la transcriptasa reversa de vih
NZ733125A (en) Isoquinoline compounds for the treatment of hiv
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
CL2011002878A1 (es) Compuestos derivados de tieno[2,3-b]piridinas, inhibidores de la replicacion del virus vih; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para prevenir o tratar una infeccion por vih.
MX2024010591A (es) Compuestos y metodos para el tratamiento de infecciones virales.
BR112012018670A2 (pt) combinação, uso de um composto, composição farmacêutica, e, pacote de paciente
CL2007002346A1 (es) Compuestos no nucleosidicos derivados de fenoxi-fenil sustituidos, inhibidores de la transcriptasa inversa del vih; composicion farmaceutica; y su uso para tratar prevenir una infeccion vih o para tratar el sida o crs.
GEAP202014873A (en) Methods for treatment and prophylaxis of hiv and aids
CO6531485A2 (es) Composiciones farmacéuticas sólidas que contienen un inhibidor de la integrasa
EP2555798A4 (en) METHOD AND COMPOSITIONS FOR INHIBITING HIV TRANSMISSIONS
CR20110184A (es) Inhibidores de la integrasa del vih
BR112016022722A2 (pt) pró-fármacos de inibidores da transcriptase reversa de hiv
CR20240365A (es) Compuestos antivirales y métodos de elaboración y uso de los mismos
MX2026002369A (es) Compuestos antivirales y metodos de elaboracion y uso de los mismos
CL2009000636A1 (es) Compuestos derivados de 1-(1h-pirazol-3-il)-imidazolidin-4-ona sustituidos; procedimiento de preparacion de los compuestos; composicion farmaceutica; y su uso en el tratamiento de enfermedades retrovirales, tal como infeccion por vih.
TW200738700A (en) HIV integrase inhibitors
SG155939A1 (en) Phosphoindoles as hiv inhibitors